Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

IQ-AI enters licensing agreement for NIMBLE app developed by Dr Joseph Bovi to treat brain metastases

IQ-AI enters licensing agreement for NIMBLE app developed by Dr Joseph Bovi to treat brain metastases

Dr Joseph Bovi from Froedtert and the Medical College of Wisconsin (MCW) joined Proactive's Stephen Gunnion with details of a novel smartphone "app" that he developed to treat brain metastases.

He explained that the NIMBLE (Network for the Integrated Management of Brain Metastases) app, engages the entire treatment team swiftly and virtually to help navigate multi-disciplinary and complex medical decisions, obviating the need for face-to-face meetings which are often difficult to coordinate.

IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) and subsidiary Imaging Biometrics have entered into an exclusive worldwide licensing agreement with MCW for the commercial rights to NIMBLE.

#ProactiveInvestors #IQ-AI #ImagingBiometrics #DrJosephBovi #NIMBLE #metastases

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK